Interleukin23 in Systemic Lupus
NCT06713187 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90
Last updated 2024-12-03
Summary
assement of interleukin 23 in serum of patients with systemic lupus erythematosus related interstial lung disease .
Conditions
- Systemic Lupus Erythematosus Related Interstial Lung Disease
Interventions
- BIOLOGICAL
-
interleukin 23
assessment of interleukin 23 in Sera of patients using ELIZA
Sponsors & Collaborators
-
Sohag University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2025-05-01
- Primary Completion
- 2025-08-01
- Completion
- 2026-06-01
Countries
- Egypt
Study Locations
More Related Trials
-
Anti KU Antibodies and Its Relationship With Systemic Lupus Erythematosus
NCT05900232 ·Status: UNKNOWN ·Phase: NA
-
Regulatory BCells in Systemic Lupus Erythematosus
NCT03178721 ·Status: UNKNOWN
-
Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus.
NCT06294483 ·Status: ENROLLING_BY_INVITATION
-
IL-26 and Systemic Lupus Erythematosus
NCT01889641 ·Status: TERMINATED
-
Correlation Between Serum Uric Acid, Serum Homocysteine Level and Interleukin- 17 in Lupus Nephritis Patients
NCT07017868 ·Status: RECRUITING
-
Serologically Active, Clinically Stable Systemic Lupus Erythematosus
NCT00000421 ·Status: COMPLETED ·Phase: PHASE2
-
Association of Serum Interleukin-33 Levels With Clinical Manifestations in Systemic Lupus Erythematosus
NCT07149402 ·Status: NOT_YET_RECRUITING
-
AntiDFS70 Lupus Nephritis
NCT06119763 ·Status: RECRUITING
-
Pilot Study - Effect of Omega-3 on Systemic Lupus Erythematosus
NCT02021513 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 623 in Subjects With Systemic Lupus Erythematosus
NCT02411136 ·Status: COMPLETED ·Phase: PHASE1
-
Immune Ablation and Hematopoietic Stem Cell Support in Patients With Systemic Lupus Erythematosus: A Phase II Study
NCT00271934 ·Status: COMPLETED ·Phase: PHASE2
-
Omalizumab for Lupus
NCT01716312 ·Status: COMPLETED ·Phase: PHASE1
-
PRediction Of Flares In Lupus With autoantibodiEs and Chemokines
NCT04951427 ·Status: UNKNOWN
-
T Regulatory Cells IN LUPUS NEPHRITIS
NCT06428539 ·Status: NOT_YET_RECRUITING
-
The Mechanisms and Significances of Synergistic Effects of Mycophenolic Acid and LPS on IL-1β Secretion by Mononuclear
NCT02435368 ·Status: UNKNOWN
-
Prognostic Factors for Fatigue in Patients With Systemic Lupus Erythematosus
NCT07123220 ·Status: COMPLETED
-
Assessment of Blood Indices in Systemic Lupus Erythematosus
NCT06872086 ·Status: NOT_YET_RECRUITING
-
Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE)
NCT00987831 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Haematological Indices in Systemic Lupus Erythematosus
NCT04110184 ·Status: UNKNOWN
-
Fatigue, Depression, and Cortical Excitability in Systemic Lupus
NCT03165682 ·Status: UNKNOWN
-
JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)
NCT06675422 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Translation of a Diagnostic Test for Lupus Flare Prediction From Bench to Clinic
NCT04018222 ·Status: UNKNOWN
-
A Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment of Patients With Active Lupus Nephritis
NCT07229742 ·Status: RECRUITING ·Phase: PHASE2
-
Chemokine (CXCL13) as Anew Marker in Diagnosis of SLE
NCT03752983 ·Status: UNKNOWN
-
Anti-infection of Low-does IL-2 in SLE
NCT02932137 ·Status: COMPLETED ·Phase: NA